Aptevo Therapeutics (APVO) Equity Average (2016 - 2023)
Historic Equity Average for Aptevo Therapeutics (APVO) over the last 8 years, with Q3 2023 value amounting to $15.5 million.
- Aptevo Therapeutics' Equity Average fell 2019.63% to $15.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $15.5 million, marking a year-over-year decrease of 2019.63%. This contributed to the annual value of $9.6 million for FY2022, which is 774.85% up from last year.
- Per Aptevo Therapeutics' latest filing, its Equity Average stood at $15.5 million for Q3 2023, which was down 2019.63% from $19.8 million recorded in Q2 2023.
- Aptevo Therapeutics' 5-year Equity Average high stood at $34.8 million for Q1 2019, and its period low was -$2.3 million during Q1 2022.
- For the 5-year period, Aptevo Therapeutics' Equity Average averaged around $15.0 million, with its median value being $13.5 million (2021).
- As far as peak fluctuations go, Aptevo Therapeutics' Equity Average tumbled by 11722.64% in 2022, and later surged by 98324.76% in 2023.
- Quarter analysis of 5 years shows Aptevo Therapeutics' Equity Average stood at $15.8 million in 2019, then tumbled by 40.49% to $9.4 million in 2020, then tumbled by 54.74% to $4.3 million in 2021, then skyrocketed by 296.52% to $16.9 million in 2022, then decreased by 8.2% to $15.5 million in 2023.
- Its Equity Average stands at $15.5 million for Q3 2023, versus $19.8 million for Q2 2023 and $20.6 million for Q1 2023.